HENLIUS (02696) announced its annual performance, with revenue of 6.67 billion RMB, representing a year-on-year growth of 16.46%.

HENLIUS (02696) announced its annual performance up to December 31, 2025. The group achieved a revenue of 6.67 billion yuan, an increase of 16.46% year-on-year; the profit attributable to owners of the parent company was 827 million yuan, an increase of 0.8% year-on-year; and the basic earnings per share were 1.52 yuan. For the year ended December 31, 2025, the group confirmed research and development expenses of approximately 2.492 billion yuan, an increase of approximately 651 million yuan from the expenses of approximately 1.8405 billion yuan in the year ended December 31, 2024. This increase was mainly used to increase investment in innovative research and development projects to accelerate the group's innovation transformation. Among them, the expense of research and development totaled approximately 1.5155 billion yuan, an increase of approximately 480 million yuan from the expenses of approximately 1.035 billion yuan in the year ended December 31, 2024. For the year ended December 31, 2025, the group's total profit was approximately 827 million yuan, an increase of approximately 6.5 million yuan from the profit of approximately 820.5 million yuan in the year ended December 31, 2024. This increase was mainly due to the continued increase in sales of core products, significant growth in overseas commercialization profits, and expansion of research and development clinical activities. Among them, overseas product profits (including overseas product supply gross profit and profit based on sales of royalties) were approximately 93.9 million yuan.